DexTech Medical AB (XSAT:DEX) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
32 GF Score
Price kr10.30
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB Research & Development?

DexTech Medical AB XSAT:DEX 32 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DexTech Medical AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

DexTech Medical AB  (XSAT:DEX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DexTech Medical AB Research & Development Related Terms

DexTech Medical AB Research & Development Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Research & Development Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:DEX
32GF Score
DexTech Medical AB XSAT:DEX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
DexTech Medical AB (XSAT:DEX) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's Research & Development too high?
DexTech Medical AB's current Research & Development is kr0.00 Mil. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Research & Development compare to VRTX and REGN?
DexTech Medical AB's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score

Get the complete analysis for XSAT:DEX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.30
Price